RxDoctor Payments Data

Nasri Ghaly, MD

Psychiatry · East Syracuse, NYNPI 1063479939

Payments from drug & device makers

$152,763in general payments, 2019–2025

Across 1,081 payments — averaging $141.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$69K
  • AbbVie$48K
  • Alkermes, Inc.$20K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$4K
  • Axsome Therapeutics, Inc.$3K
  • Vanda Pharmaceuticals Inc.$1K
  • plus $8K from 29 others

What the payments were for

  • Consulting fees$2,8982%
  • Speaking & faculty fees$123,74181%
  • Travel & lodging$5,0133%
  • Food & beverage$20,36813%
  • Education$7440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$152,763 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$198,533
Medicare patients
289
Services billed
2,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl34$94,640
RexultiBrexpiprazole55$66,188
VraylarCariprazine Hcl28$35,921
TrintellixVortioxetine Hydrobromide38$23,590
NucyntaTapentadol Hcl27$20,913
Lurasidone Hcl57$15,631
SunosiSolriamfetol Hcl24$14,237
Asenapine Maleate24$8,040
LexaproEscitalopram Oxalate21$7,439
Desvenlafaxine Succinate ErDesvenlafaxine Succinate90$6,753
BelsomraSuvorexant16$6,566
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl73$6,234
AzstarysSerdexmethylphen/Dexmethylphen12$5,029
Clozapine89$4,339
Olanzapine OdtOlanzapine26$3,899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$793$94,64034 claims
Otsuka America Pharmaceutical, Inc.Rexulti$846$66,18855 claims
AbbVieVraylar, Lexapro$47,948$43,36049 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$682$23,59038 claims
Axsome Therapeutics, Inc.Sunosi$2,835$14,23724 claims
MerckBelsomra$28$6,56616 claims
Corium, LLCAzstarys$131$5,02912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in East Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →